The abortion drug is responsible for the deaths of dozens of women worldwide, including several in the United States alone, and it has injured at least 1,100 women in the United States alone as of 2006 figures from the Food and Drug Administration. But that didn’t stop the Obama administration from allowing Planned Parenthood and other abortion businesses to expand usage of the drug to include uses that the FDA once condemned.
The dangerous RU 486 abortion drug has nearly claimed the lives of two million unborn children in the United States since its approval at the end of the Clinton administration. In addition to the number of unborn children whose lives have been lost to the abortion drug, women have suffered as well, as a Planned Parenthood study admits at least one woman is seriously injured from the abortion pill daily.
Because of the high failure rate and the risks involved with RU-486 in later pregnancies, the FDA limited approval for use only in the first 49 days from the start of a woman’s last menstrual period. Planned Parenthood, by its own admission, ignores this limitation.
Despite that, the Obama administration gave to Planned Parenthood’s demands last month and altered the approved use of Mifeprex, (also known as Mifepristone or RU486), to come in line with off-label protocols used by Planned Parenthood and other abortion businesses. The FDA hannounced that it is extending the allowed time period for use of the abortion drug to 70 days.
Now, U.S. Rep. Chris Smith (NJ-04) and Senator James Lankford (OK), joined by 73 of their colleagues, sent a bicameral letter to the U.S. Food and Drug Administration (FDA) expressing concern and requesting information about the agency’s recent decision to change its policies regarding the abortion drug mifepristone.
The letter says in part:
“We are deeply disappointed to learn that you have loosened FDA standards governing use of the abortion drug mifepristone, also referred to as Mifeprex or RU-486. This powerful abortion drug has been associated with serious adverse events including hemorrhaging, severe infections and even deaths of mothers who have taken it.”
In the letter the lawmakers seek additional information in light of the controversial origins of the original approval of mifepristone in the United States. At the beginning of the Clinton administration, Clinton issued an executive order instructing the FDA to re-evaluate the status of RU-486. Then-FDA Commissioner Kessler even urged the European patent-holder, Roussel Uclaf, to submit an application for approval of what was then called RU-486. When mainstream drug manufacturers refused to bring this baby-killing drug to the United States, the Population Council licensed the drug and abortion proponents created a corporation, DANCO, for one purpose and one purpose only: to distribute mifepristone in the United States. Headquartered in the Cayman Islands, DANCO had the abortion drug manufactured in China and packaged in New Jersey.